The latest approved Alzheimer’s drug, Lecanemab, shows a cognitive benefit. It’s modest, but there are already successors in the pipeline that have shown promise (e.g. donanemab). They’re baby steps, not at all cures, and have significant side effects, but “everything we try doesn’t work at all” isn’t really true the way it was even a few years ago.